TrialCancer2012

Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity.

Clara Curiel-Lewandrowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.